Edwards Lifesciences (EW) has issued an announcement.
Edwards Lifesciences Corporation has announced a landmark deal to sell its Critical Care product group to Becton, Dickinson and Company for $4.2 billion, abandoning a previously planned spin-off of the business. The cash acquisition is subject to customary closing conditions, including antitrust and foreign investment approvals. While optimistic, the company cautions that forward-looking statements involve risks and uncertainties that could impact the transaction’s completion and the company’s future results.
Learn more about EW stock on TipRanks’ Stock Analysis page.